The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.

The trial showed a 'clinically meaningful' and 'statistically significant' improvement when treated with therapy plus BCG, ...

Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...

Pfizer PFE announced positive results from the phase III CREST study that evaluated its investigational PD-1 inhibitor ...

If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...

Sasanlimab, a subcutaneous immunotherapy developed by Pfizer, could help treat bladder cancer. Elsewhere, Royalty Pharma ...

Pfizer on Friday said the pivotal Phase 3 study evaluating sasanlimab in combination with standard-of-care Bacillus Calmette-Guerin, or BCG, as induction therapy with or without maintenance in ...

Pfizer’s “golden egg” has hatched. The subcutaneous PD-1 inhibitor improved outcomes when added to the standard of care in ...

Pfizer Inc. (NYSE:PFE) released topline results from its Phase 3 CREST trial evaluating sasanlimab, an investigational ...

Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 ...

(RTTNews) - Pfizer Inc. (PFE), on Friday, announced that its pivotal Phase 3 trial of investigational anti-PD-1 monoclonal antibody, Sasanlimab, in patients with BCG-naïve, high-risk non-muscle ...